APA

Eiznhamer D. A., Creagh T., Ruckle J. L., Tolbert D. T., Giltner J., Dutta B., Flavin M. T., Jenta T. & Xu Z. (20030213). Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. : HIV clinical trials.

Chicago

Eiznhamer David A, Creagh Terri, Ruckle Jon L, Tolbert Dwain T, Giltner Jeremy, Dutta Bipul, Flavin Michael T, Jenta Tuah and Xu Ze-Qi. 20030213. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. : HIV clinical trials.

Harvard

Eiznhamer D. A., Creagh T., Ruckle J. L., Tolbert D. T., Giltner J., Dutta B., Flavin M. T., Jenta T. and Xu Z. (20030213). Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. : HIV clinical trials.

MLA

Eiznhamer David A, Creagh Terri, Ruckle Jon L, Tolbert Dwain T, Giltner Jeremy, Dutta Bipul, Flavin Michael T, Jenta Tuah and Xu Ze-Qi. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. : HIV clinical trials. 20030213.